ARCHIVES

Nevins Retracts Key Paper By Duke Group, Raising Question Of Harm To Patients

This article is from The Cancer Letter archive.

Vol. 36 No. 39 | October 29, 2010

Download PDF Visit The Full Archive

Related Articles

New Partnership To Guide National 5 A Day Program.

August 31, 2001

ASCO And ESMO Publish Training Recommendations

November 26, 2004

Amgen’s Aranesp Sales Dropped By Half, Continue To Fall.

November 14, 2008

Racial Disparities Remain In Breast Cancer Care

October 29, 2010

Wyden Asks Healy To Clarify CRADA Pricing Clause

January 3, 1992

In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says

February 12, 1999